An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
IN8bio, Inc. (Nasdaq: INAB) will present on Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product at the ASGCT 2024 Annual Meeting. The presentation focuses on novel production platforms and will take place on May 10th, 2024, in Baltimore, MD. The data will be available online post-presentation.
IN8bio, Inc. (Nasdaq: INAB) presenterà sul confronto tra i prodotti Deltex DRI provenienti da donatori sani e pazienti autologi durante l'incontro annuale ASGCT 2024. La presentazione si concentrerà su nuove piattaforme di produzione e si terrà il 10 maggio 2024, a Baltimore, MD. I dati saranno disponibili online dopo la presentazione.
IN8bio, Inc. (Nasdaq: INAB) presentará sobre el Producto Deltex DRI fabricado por Donantes Saludables versus Pacientes Autólogos en la Reunión Anual de ASGCT 2024. La presentación se centrará en plataformas de producción innovadoras y tendrá lugar el 10 de mayo de 2024, en Baltimore, MD. Los datos estarán disponibles en línea después de la presentación.
IN8bio, Inc. (나스닥: INAB)는 2024년 ASGCT 연례 회의에서 건강한 기증자 대 자가 제조 자가용 Deltex DRI 제품에 대해 발표할 예정입니다. 발표는 새로운 생산 플랫폼에 초점을 맞출 것이며, 2024년 5월 10일에 메릴랜드주 볼티모어에서 진행됩니다. 발표 후 데이터는 온라인에서 확인할 수 있습니다.
IN8bio, Inc. (Nasdaq: INAB) présentera sur le Produit Deltex DRI fabriqué par des Donneurs Sains vs des Patients Autologues lors de la Réunion Annuelle de l'ASGCT 2024. La présentation se focalisera sur de nouvelles plateformes de production et aura lieu le 10 mai 2024 à Baltimore, MD. Les données seront disponibles en ligne après la présentation.
IN8bio, Inc. (Nasdaq: INAB) wird auf der ASGCT Jahrestagung 2024 über die autologe Deltex DRI-Produkte von gesunden Spendern im Vergleich zu Patienten referieren. Die Präsentation konzentriert sich auf neue Produktionsplattformen und findet am 10. Mai 2024 in Baltimore, MD statt. Die Daten werden nach der Präsentation online verfügbar sein.
Positive
None.
Negative
None.
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET
Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.
Corporate Contact: IN8bio, Inc. Glenn Schulman, PharmD, MPH 203.494.7411 gdschulman@IN8bio.com
in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.
